Form 4 for JNJ Johnson & Johnson
Accepted 2024-02-12 19:25:22 ET · period of report 2024-02-08 · accession 0001225208-24-001900 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-12 19:25 | 2024-02-08+ | JNJ | Taubert Jennifer L | EVP, WW COB, Pharmaceuticals | M - OptEx | $85.08 | +63.1K | 200.8K | +46% | +$5.37M |
| D | 2024-02-12 19:25 | 2024-02-08 | JNJ | Taubert Jennifer L | EVP, WW COB, Pharmaceuticals | F - Tax | $156.33 | -1,913 | 141.4K | -1% | -$299.1K |
| D | 2024-02-12 19:25 | 2024-02-09 | JNJ | Taubert Jennifer L | EVP, WW COB, Pharmaceuticals | S - Sale+OE | $156.27 | -59.4K | 141.4K | -30% | -$9.28M |
| DM | 2024-02-12 19:25 | 2024-02-08+ | JNJ | Taubert Jennifer L | EVP, WW COB, Pharmaceuticals | M - OptEx | $0.00 | -63.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-08 | M | A | 3,739 | $0.00 | 143,329.00 | D | — | — | (F1) Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. |
| 2 | Common | Common Stock | 2024-02-08 | F | D | 1,913 | $156.33 | 141,416.00 | D | — | — | (F2) Shares withheld for payment of taxes upon vesting of Restricted Share Units. |
| 3 | Common | Common Stock | 2024-02-09 | M | A | 59,397 | $90.44 | 200,813.00 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-09 | S | D | 59,397 | $156.27 | 141,416.00 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $156.180 to $156.360. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Derivative | Restricted Share Units | 2024-02-08 | M | D | 3,739 | $0.00 | 0 | D | — · 2024-02-08 to — | 3,739 Common Stock | (F1) Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. (F1) Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. (F1) Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. |
| 6 | Derivative | Employee Stock Options (Right to Buy) | 2024-02-09 | M | D | 59,397 | $0.00 | 0 | D | $90.44 · 2017-02-11 to 2024-02-09 | 59,397 Common Stock |